Brian Hill, MD, reviews the case of a 73-year-old man with mantle cell lymphoma.
A 73-Year-Old Male With Mantle Cell Lymphoma
Brian Hill, MD, reviews frontline treatment options for patients with mantle cell lymphoma.
Brian Hill, MD, reviews second-line treatment options for patients with relapsed/refractory mantle cell lymphoma.
Brian Hill, MD, reviews practice-changing data from the ZUMA-2 trial in patients with relapsed/refractory mantle cell lymphoma.
Brian Hill, MD, reviews strategies for mitigating toxicities associated with CAR T-cell therapy.
Brian Hill, MD, reviews the role of CAR T-cell therapy in mantle cell lymphoma.
Brian Hill, MD, reviews unmet needs and future directions in the management of mantle cell lymphoma.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
